News

EU monitors bioeconomy
Enlarge image

PolicyEU

EU monitors bioeconomy

19.02.2013 - The European Commission has announced it will launch an observatory to map progress and impact of the development of the EU's bioeconomy.

The observatory, which is part of the EC's bioeconomy action plan, will gather data to follow the evolution of markets, to map EU, national and regional bioeconomy policies, research and innovation capacities, and the scale of related public and private investments. The Commission's in-house science service JRC will run the new resource.

"It's now one year since we launched our bioeconomy strategy“, said Research Commissioner Máire Geoghegan-Quinn in Brussels. „We are now seeing Member States seize the opportunity offered by the transition to a post-petroleum economy based on smart use of resources from land and sea. It's essential that they do because it will be good for our environment, our food and energy security, and for Europe's competitiveness in the future. This observatory will help keep the momentum going."

The observatory will start its 3-year term in March 2013 with the aim of making the data it will collect publicly available through a dedicated web portal in 2014. In this way, the observatory will support the regional and national bioeconomy strategies now being developed by EU Member States. The observatory will track a number of performance measures, including economic and employment indicators, innovation indicators, and measures of productivity, social wellbeing and environmental quality. It will also provide a "technology watch” and “policy watch” and will follow the development of science and technology.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/commission-monitors-bioeconomy.html

BusinessUK

03.03.2015 After weeks of speculation, AstraZeneca has announced its plans to spin out its early-stage antibiotic R&D. The decision marks the company’s aims to “sharpen its focus on three main therapy areas”.

GenericsEUUKHungaryGermanyItalyGreeceAustriaLuxembourgFranceSpain

26.02.2015 It is the first biosimilar monoclonal antibody in many European markets: Mundipharma and Hospira are launching Celltrion’s Remicade generic.

M&AUK

23.02.2015 British drug developer Heptares has been acquired by Japanese biopharma play Sosei for US$400m (€352m).

bioethanolGermanyUKBelgiumFrance

19.02.2015 The price of oil has been sliding for months, and the European bioethanol market is taking it hard. CropEnergies AG has now stopped production at its British unit Ensus UK.

BusinessFranceGermany

17.02.2015 After Christopher Viehbacher’s unceremonious ousting last year, Sanofi has been on the look out for a new CEO. Now, sources say Bayer’s Olivier Brandicourt is set to fill the position.

BusinessUKSwitzerland

12.02.2015 Glaxosmithkline is intent on bolstering its vaccine portfolio further and has bought all shares of Swiss development partner Glycovaxyn.

InvestmentsUKEU

10.02.2015 Interest in biotechnology is on the rise among British investors. Not just one, but two major financiers are planning investment funds in the field.

IVFUKEU

04.02.2015 In a historic move, the UK is set to become the first country to allow the creation of babies with the genetic material of three people – a mother, a father and a female mitochondrial donor.

Events

All Events

Partner-Events

Planegg/Martinsried

1st Munich Biotech Pitch

Berlin (DE)

Proteomic Forum 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MEDIGENE4.64 EUR7.16%
  • FORMYCON16.89 EUR4.07%
  • BIOFRONTERA1.99 EUR3.65%

FLOP

  • HBM102.00 CHF-2.86%
  • SYNGENTA327.00 CHF-2.15%
  • STRATEC BIOMEDICAL45.12 EUR-2.10%

TOP

  • WILEX3.17 EUR48.8%
  • EVOLVA1.70 CHF18.9%
  • MEDIGENE4.64 EUR16.6%

FLOP

  • MOLOGEN5.25 EUR-14.1%
  • SANTHERA98.45 CHF-10.3%
  • 4SC0.77 EUR-9.4%

TOP

  • SANTHERA98.45 CHF2457.1%
  • WILEX3.17 EUR403.2%
  • FORMYCON16.89 EUR115.7%

FLOP

  • CYTOS0.37 CHF-86.9%
  • MOLOGEN5.25 EUR-57.4%
  • PAION2.10 EUR-55.3%

No liability assumed, Date: 04.03.2015